展望CD3的未来,T细胞对血液性恶性瘤的双特异性抗体进行激活
Daniel R Reed1, Lawrence G Lum1
1Department of Medicine, Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA.
Expert opinion on biological therapy
|July 29, 2024
概括
双特异性抗体正在彻底改变血液癌症的治疗方法,在淋巴瘤,白血病和髓瘤中取得了成功. 需要对急性髓性白血病进行进一步的研究,并优化当前的治疗方法,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自从2017年blinatumomab获得批准以来,双特异性抗体的开发在治疗血液性恶性瘤方面取得了快速进展.
- 许多双特异性抗体结构已获得监管部门的批准,用于治疗淋巴瘤,白血病和多发性骨髓瘤.
研究的目的:
- 审查用于血液恶性瘤的双特异性抗体治疗方法.
- 涵盖各种双特异性抗体结构的机制,指示,疗效,毒性和挑战.
主要方法:
- 使用PubMed和clinicaltrials.gov进行了文献搜索.
主要成果:
- 双特异性抗体在治疗非霍奇金淋巴瘤 (NHL),多发性骨髓瘤 (MM) 和急性淋巴细胞白血病 (ALL) 中取得了显著的成功.
- 使用这些药物治疗急性髓性白血病 (AML) 的进展有限.
结论:
- 对新型设计和瘤抗原点的持续调查至关重要.
- 优化当前两种特异性抗体疗法的测序对于改善血液癌症患者的结果至关重要.
相关概念视频
01:22T Cell Activation and Clonal Selection
13.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K